Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post-refractive IOL Outcomes With Clareon TruPlus

NCT: NCT07610226 · NOT_YET_RECRUITING

NCT IDNCT07610226
StatusNOT_YET_RECRUITING
Start Date2026-06-23
Completion2027-06-23

Brief Summary

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

Frequently Asked Questions

What is Post-refractive IOL Outcomes With Clareon TruPlus?

Post-refractive IOL Outcomes With Clareon TruPlus is a clinical trial registered under NCT07610226. Current status: NOT_YET_RECRUITING.

What is the status of NCT07610226?

The current status of NCT07610226 (Post-refractive IOL Outcomes With Clareon TruPlus) is: NOT_YET_RECRUITING.

When did Post-refractive IOL Outcomes With Clareon TruPlus start?

Post-refractive IOL Outcomes With Clareon TruPlus started on 2026-06-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.